tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

JMP downgrades Intellia on lack of 2023 clinical updates

JMP Securities analyst Silvan Tuerkcan downgraded Intellia Therapeutics to Market Perform from Outperform without a price target. The analyst views the shares as fairly valued at current levels. Moving in-vivo editing to the U.S. will represent a major milestone, but there is little upside for the stock with more downside risk as the company engages regulators, Tuerkcan tells investors in a research note. The analyst says 2023 will bring little in terms of clinical updates for Intellia with the focus on regulatory interactions.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on NTLA:

Disclaimer & DisclosureReport an Issue

1